Zimbabwe has declined a substantial US health deal valued at $367m (£272m) over five years because of Washington's request for sensitive information.
This rejection was revealed following a government memo from December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "skewed".
A government representative later stated that the United States was seeking health data for scientific study and commercial purposes but was unwilling to share the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued negotiations to reach a deal suitable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Context
Zimbabwe's decision follows a similar case in Kenya, where a high court suspended a related health funding agreement following concerns were filed about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have to date signed these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment through US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to share its genetic material and health information over an extended period, without any equivalent assurance of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Put simply, our nation would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our citizens if a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one health agreements were disrupting structures already set up via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with future global health emergencies.
"This system is designed to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We are open to further discussions with our US partners on how future co-operation could be designed in a manner that honours the independence and dignity of both nations."
Medical Community Response
A leading public health body said it acknowledged the government's concerns, but recommended that negotiations must proceed considering a large portion of the nation's Aids initiatives were funded by external financing.
"Where specific concerns exist, such as those relating to data governance or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," it said.
The situation emphasises the continuing tensions between accepting vital foreign assistance and protecting local interests in an increasingly data-driven world.